Who Pays My Doctor?

Healthcare provider profile · identity verified

Douglas Hogarth

Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · CHICAGO, IL · NPI 1619030137

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Douglas Hogarth received $426,297.36 in general payments during 2025 across 549 reported records.

AstraZeneca Pharmaceuticals LP accounted for 40.4% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 21 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Glassia, Tezspire.

Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEZSPIRE as an associated drug or biological on 22824 records involving 7320 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Tezspire by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Bevespi Aerosphere by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Symbicort by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEZSPIRE as an associated drug or biological on 33983 records involving 10291 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Tezspire by this doctor in 2024.

GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Trelegy Ellipta by this doctor in 2024.

Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAGARD LIQUID as an associated drug or biological on 29 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Gammagard Liquid by this doctor in 2024.

Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GLASSIA as an associated drug or biological on 7881 records involving 3215 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Glassia by this doctor in 2024.

Vifor Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Zemaira as an associated drug or biological on 1409 records involving 818 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Zemaira by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$426,297.36

549 reported records · 21 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
AstraZeneca Pharmaceuticals LP Unresolved — no canonical attribution shown $172,140.6140.4%1792025
Noah Medical Corporation Unresolved — no canonical attribution shown $141,677.3433.2%1942025
Grifols USA, LLC Unresolved — no canonical attribution shown $48,438.0811.4%402025
Olympus America Inc. Unresolved — no canonical attribution shown $29,585.626.9%562025
Pulmonx Corporation Unresolved — no canonical attribution shown $12,706.873.0%232025
Takeda Pharmaceuticals U.S.A., Inc. Unresolved — no canonical attribution shown $9,651.992.3%202025
Olympus Corporation of the Americas Unresolved — no canonical attribution shown $6,412.371.5%52025
GENZYME CORPORATION Unresolved — no canonical attribution shown $3,236.030.8%32025
Serpex Medical Inc Unresolved — no canonical attribution shown $1,159.110.3%22025
Ambu A/S Unresolved — no canonical attribution shown $520.000.1%12025
Verona Pharma, Inc. Unresolved — no canonical attribution shown $169.060.0%42025
Regeneron Healthcare Solutions, Inc. Unresolved — no canonical attribution shown $143.930.0%42025
GlaxoSmithKline, LLC. Unresolved — no canonical attribution shown $106.120.0%62025
Genentech USA, Inc. Unresolved — no canonical attribution shown $100.580.0%42025
Galvanize Therapeutics, Inc Unresolved — no canonical attribution shown $80.130.0%22025
Gyrus ACMI, Inc. Unresolved — no canonical attribution shown $59.590.0%12025
Mallinckrodt Hospital Products Inc. Unresolved — no canonical attribution shown $40.810.0%12025
Amgen Inc. Unresolved — no canonical attribution shown $22.920.0%12025
Electromed, Inc. Unresolved — no canonical attribution shown $19.990.0%12025
Vifor Pharma, Inc. Unresolved — no canonical attribution shown $17.360.0%12025
INTUITIVE SURGICAL, INC. Unresolved — no canonical attribution shown $8.850.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program$211,249.7575
Consulting Fee$69,458.0049
Education$69,136.2519
Travel and Lodging$62,926.21169
Food and Beverage$13,007.15236
Honoraria$520.001

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
GALAXY
Normalized: galaxy		 Device Noah Medical Corporation $141,677.34 194 2025
Source payment records
TEZSPIRE
Normalized: tezspire		 Biological Amgen Inc., AstraZeneca Pharmaceuticals LP $87,796.94 95 2025
Source payment records
FASENRA
Normalized: fasenra		 Biological AstraZeneca Pharmaceuticals LP $83,253.55 81 2025
Source payment records
Prolastin-C Liquid
Normalized: prolastin c liquid		 Biological Grifols USA, LLC $48,438.08 40 2025
Source payment records
Spiration Valve System
Normalized: spiration valve system		 Device Gyrus ACMI, Inc., Olympus America Inc., Olympus Corporation of the Americas $35,714.55 57 2025
Source payment records
ZEPHYR ENDOBRONCHIAL VALVE
Normalized: zephyr endobronchial valve		 Device Pulmonx Corporation $12,706.87 23 2025
Source payment records
GLASSIA
Normalized: glassia		 Biological Takeda Pharmaceuticals U.S.A., Inc. $9,651.99 20 2025
Source payment records
CHARTIS CATHETER
Normalized: chartis catheter		 Device Pulmonx Corporation $7,522.06 16 2025
Source payment records
PULMONX CHARTIS TABLET CONSOLE
Normalized: pulmonx chartis tablet console		 Device Pulmonx Corporation $7,522.06 16 2025
Source payment records
ZEPHYR DELIVERY CATHETER
Normalized: zephyr delivery catheter		 Device Pulmonx Corporation $7,522.06 16 2025
Source payment records
Single-Use flexible Video Bronchoscope
Normalized: single use flexible video bronchoscope		 Device Olympus America Inc. $5,240.00 2 2025
Source payment records
DUPIXENT
Normalized: dupixent		 Biological GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. $208.96 6 2025
Source payment records
Ohtuvayre
Normalized: ohtuvayre		 Drug Verona Pharma, Inc. $169.06 4 2025
Source payment records
NUCALA
Normalized: nucala		 Biological GlaxoSmithKline, LLC. $106.12 6 2025
Source payment records
Xolair
Normalized: xolair		 Biological Genentech USA, Inc. $100.58 4 2025
Source payment records
ALIYA SYSTEM
Normalized: aliya system		 Device Galvanize Therapeutics, Inc $80.13 2 2025
Source payment records
ACTHAR
Normalized: acthar		 Biological Mallinckrodt Hospital Products Inc. $40.81 1 2025
Source payment records
BREZTRI
Normalized: breztri		 Drug AstraZeneca Pharmaceuticals LP $40.56 2 2025
Source payment records
SMARTVEST
Normalized: smartvest		 Device Electromed, Inc. $19.99 1 2025
Source payment records
Veltassa
Normalized: veltassa		 Drug Vifor Pharma, Inc. $17.36 1 2025
Source payment records
Da Vinci Surgical System
Normalized: da vinci surgical system		 Device INTUITIVE SURGICAL, INC. $8.85 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments productPayment yearPart D brandPart D yearClaimsMatch methodSource
GLASSIA
glassia		 2025 Glassia 2024 65
Beneficiary count suppressed		 exact normalized Medicare Part D
TEZSPIRE
tezspire		 2025 Tezspire 2024 25
Beneficiary count suppressed		 exact normalized Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying companyPayment yearDrug reported by same entityOpen Payments evidencePart DClaimsBeneficiaries
Amgen Inc.
Exact reporting entity; no affiliate inference		 2025 TEZSPIRE
open payments reported associated product		 CMS Open Payments — General Payments
22824 supporting records · 7320 recipient NPIs · example record 1226871881 		Tezspire · 2024
Exact normalized brand match · 1 Part D row		 25 suppressed by CMS
AstraZeneca Pharmaceuticals LP
Exact reporting entity; no affiliate inference		 2025 BEVESPI AEROSPHERE
open payments reported associated product		 CMS Open Payments — General Payments
763 supporting records · 473 recipient NPIs · example record 1206131384 		Bevespi Aerosphere · 2024
Exact normalized brand match · 1 Part D row		 14 suppressed by CMS
AstraZeneca Pharmaceuticals LP
Exact reporting entity; no affiliate inference		 2025 SYMBICORT
open payments reported associated product		 CMS Open Payments — General Payments
71 supporting records · 51 recipient NPIs · example record 1206132610 		Symbicort · 2024
Exact normalized brand match · 1 Part D row		 39 suppressed by CMS
AstraZeneca Pharmaceuticals LP
Exact reporting entity; no affiliate inference		 2025 TEZSPIRE
open payments reported associated product		 CMS Open Payments — General Payments
33983 supporting records · 10291 recipient NPIs · example record 1206131392 		Tezspire · 2024
Exact normalized brand match · 1 Part D row		 25 suppressed by CMS
GlaxoSmithKline, LLC.
Exact reporting entity; no affiliate inference		 2025 TRELEGY ELLIPTA
open payments reported associated product		 CMS Open Payments — General Payments
131532 supporting records · 37148 recipient NPIs · example record 1190332369 		Trelegy Ellipta · 2024
Exact normalized brand match · 1 Part D row		 92 21
Takeda Pharmaceuticals U.S.A., Inc.
Exact reporting entity; no affiliate inference		 2025 GAMMAGARD LIQUID
open payments reported associated product		 CMS Open Payments — General Payments
29 supporting records · 8 recipient NPIs · example record 1223786557 		Gammagard Liquid · 2024
Exact normalized brand match · 1 Part D row		 12 suppressed by CMS
Takeda Pharmaceuticals U.S.A., Inc.
Exact reporting entity; no affiliate inference		 2025 GLASSIA
open payments reported associated product		 CMS Open Payments — General Payments
7881 supporting records · 3215 recipient NPIs · example record 1223616286 		Glassia · 2024
Exact normalized brand match · 1 Part D row		 65 suppressed by CMS
Vifor Pharma, Inc.
Exact reporting entity; no affiliate inference		 2025 Zemaira
open payments reported associated product		 CMS Open Payments — General Payments
1409 supporting records · 818 recipient NPIs · example record 1172020727 		Zemaira · 2024
Exact normalized brand match · 1 Part D row		 23 suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Albuterol Sulfate HfaAlbuterol Sulfate13642
Prolastin CAlpha-1-Proteinase Inhibitor9711
Trelegy ElliptaFluticasone/Umeclidin/Vilanter9221
PrednisonePrednisone8937
Spiriva RespimatTiotropium Bromide6615
GlassiaAlpha-1-Proteinase Inhibitor65suppressed
AzithromycinAzithromycin5224
Incruse ElliptaUmeclidinium Bromide43suppressed
Spiriva HandihalerTiotropium Bromide4312
SymbicortBudesonide/Formoterol Fumarate39suppressed
Breztri AerosphereBudesonide/Glycopyr/Formoterol32suppressed
Aralast NpAlpha-1-Proteinase Inhibitor28suppressed
Fluticasone-SalmeterolFluticasone Propion/Salmeterol28suppressed
Breo ElliptaFluticasone/Vilanterol27suppressed
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr25suppressed
TezspireTezepelumab-Ekko25suppressed
ZemairaAlpha-1-Proteinase Inhibitor23suppressed
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate20suppressed
Fasenra PenBenralizumab20suppressed
Montelukast SodiumMontelukast Sodium18suppressed
Stiolto RespimatTiotropium Br/Olodaterol Hcl18suppressed
Ventolin HfaAlbuterol Sulfate15suppressed
Advair DiskusFluticasone Propion/Salmeterol14suppressed
Bevespi AerosphereGlycopyrrolate/Formoterol Fum14suppressed
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5012suppressed
Tramadol HclTramadol Hcl11suppressed
Wixela InhubFluticasone Propion/Salmeterol11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $426,297.36 · 549 records AstraZeneca Pharmaceuticals LP ACTHAR, ALIYA SYSTEM, BREZTRI, CHARTIS CATHETER, DUPIXENT, Da Vinci Surgical System, FASENRA, GALAXY, GLASSIA, NUCALA, Ohtuvayre, PULMONX CHARTIS TABLET CONSOLE, Prolastin-C Liquid, SMARTVEST, Single-Use flexible Video Bronchoscope, Spiration Valve System, TEZSPIRE, Veltassa, Xolair, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE 8 —
2024 — — — — Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error